A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment

Clinical trial NCT06922929 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06922929
Sponsor: Yunhe Pharmaceutical (Tianjin) Co., Ltd
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Prostate Cancer Recurrent

Start date: 2025-04-01
Primary completion: 2027-04-01
Enrollment: 110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.